Key Points
- COO Joseph Gilliam sold 19,340 shares at an average price of $90 on Nov. 18 for $1,740,600, reducing his ownership by 17.31% to 92,366 shares (≈$8.31M), according to an SEC filing.
- Glaukos reported Q results with EPS of ($0.16), beating estimates by $0.11, and revenue of $133.54M (up 38.1% YoY), but remains unprofitable with a -18.65% net margin and negative ROE.
- The stock carries a $5.47B market cap and a 52-week range of $73.16–$163.71, has a consensus rating of "Moderate Buy" with a $119.08 target, and is 99.04% institutionally owned.
Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 19,340 shares of the stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the transaction, the chief operating officer directly owned 92,366 shares in the company, valued at approximately $8,312,940. The trade was a 17.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Glaukos Stock Performance
NYSE GKOS opened at $95.26 on Friday. The firm has a market capitalization of $5.47 billion, a P/E ratio of -61.86 and a beta of 0.81. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The stock's fifty day moving average is $84.38 and its two-hundred day moving average is $91.32. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $163.71.
Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The company had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. During the same quarter last year, the firm posted ($0.28) earnings per share. Glaukos's revenue was up 38.1% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Glaukos Corporation will post -1.08 earnings per share for the current year.
Hedge Funds Weigh In On Glaukos
A number of hedge funds have recently modified their holdings of GKOS. CANADA LIFE ASSURANCE Co lifted its position in Glaukos by 0.8% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 61,348 shares of the medical instruments supplier's stock worth $4,986,000 after acquiring an additional 514 shares during the last quarter. Verition Fund Management LLC bought a new stake in shares of Glaukos in the 3rd quarter valued at approximately $579,000. Qube Research & Technologies Ltd lifted its holdings in shares of Glaukos by 87.2% during the third quarter. Qube Research & Technologies Ltd now owns 367,528 shares of the medical instruments supplier's stock valued at $29,972,000 after acquiring an additional 171,163 shares during the period. RA Capital Management L.P. bought a new stake in Glaukos during the third quarter worth about $4,418,000. Finally, Prelude Capital Management LLC bought a new position in Glaukos in the 3rd quarter valued at $669,000. 99.04% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts have weighed in on GKOS shares. Mizuho set a $130.00 price objective on Glaukos in a report on Thursday, July 31st. BTIG Research increased their price objective on Glaukos from $104.00 to $116.00 and gave the company a "buy" rating in a research note on Thursday, October 30th. UBS Group reiterated a "buy" rating and set a $140.00 target price on shares of Glaukos in a research report on Monday, November 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Glaukos in a report on Wednesday, October 8th. Finally, Stifel Nicolaus set a $115.00 price target on Glaukos in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $119.08.
Get Our Latest Report on Glaukos
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
